Skip to main content
OpenTrials
Completed

NCT Number: NCT02418728

The Role of Atrial Natriuretic Peptide in the Lipolytic Process: Effect of Obesity and Exercise

In the developing countries, obesity prevalence is on a dramatic rise. Obesity is related to co-morbidities and as a result, obesity significantly shortens life expectancy and lowers quality of life. To prevent this, participation in exercise or training programs is absolutely necessary, in order to generate adipose tissue mass loss. The amount of adipose tissue mass loss is, amongst others, dependent on lipolysis which is under endocrine regulation by, mainly, catecholamines, insulin and atrial natriuretic peptide. However, large variations in adipose tissue mass loss and gain are likely in obese subjects, possibly due to a decreased lipolytic effect of these hormones (as was shown for catecholamines in the subcutaneous adipose tissue of obese subjects). However, the relative contribution of atrial natriuretic peptide in the lipolytic process remains elusive, particularly in subjects with obesity, which show an increased plasma expression of atrial natriuretic peptide.

The aim of the present study is to observe the contribution of atrial natriuretic peptide in the subcutaneous adipose tissue of obese subjects. This will be tested by measurements of extracellular glycerol levels (by microdialysis) in the subcutaneous adipose tissue in situ at rest and during endurance exercise under local beta- and alpha-blockade.

Eventually, the knowledge gained from this research will contribute to the optimization of exercise programs for people with obesity.

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–60 year

Sex eligibility

Male

Study type

Observational

Primary location

Hasselt University

Diepenbeek, 3590, Belgium

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Obese group: BMI > 30 kg/m², sedentary (no regular physical activity last 6 months), insulin sensitive or insulin resistant
  • Lean controls: BMI > 18.5 kg/m² and < 25 kg/m², regular physical activity, insulin sensitive

Exclusion criteria

  • Regular glucose lowering medication or beta blockade medication
  • Presence of chronical diseases
  • Orthopedic or neurological problems

Treatment and study plan

subcutaneous adipose tissue microdialysis under local beta/alpha blockade

Other

adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis

Primary outcomes

  1. Subcutaneous adipose tissue microdialysis

    Time frame: week 1

    abdominal subcutaneous adipose tissue microdialysis during rest and exercise; basal + under local alpha- and beta-blockade.

  2. Atrial natriuretic peptide (ANP) Response

    Time frame: week 1

    measurement systemic ANP response (venous blood sampling)

Secondary outcomes

  1. Central insulin sensitivity

    Time frame: screening

    Fasting serum insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity derived from an oral glucose tolerance test (75g)

  2. Echocardiography

    Time frame: Day 1

    heart function by means of standard echocardiography

  3. Maximal oxygen uptake (ml/O2/kg/min)

    Time frame: Day 1

    measured using indirect calorimetry and an incremental bicycle protocol

  4. Anthropometry

    Time frame: screening

    body composition, measured using dual x-ray absorptiometry, height, weight, waist and hip circumference

  5. Abdominal subcutaneous adipose tissue biopsy

    Time frame: week 1

    biochemical, proteomics and morphological analyses

Sponsors and collaborators

Lead sponsor

Hasselt University

Other

Collaborators

  • Jessa Hospital
  • Maastricht University

Registry information

Official study title

The Contribution of Atrial Natriuretic Peptide in Lipid Mobilization of Subjects With Obesity, Both During Rest and Exercise

Acronym: BALO

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Apr 16, 2015
Registry last updated
Nov 18, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.